Abeona Therapeutics Inc at Jefferies Healthcare Conference Transcript
Hi, good morning, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the Abeona team today who's here for a fireside chat, maybe if you want to provide a brief intro to the company, and then we'll jump into questions for the fireside.
Good morning, everyone, and thank you very much for having us here, Maury. And I am Vish Seshadri, the CEO of Abeona Therapeutics, very happy to share today our company, which is a late clinical-stage, BLA-stage, cell and gene therapy company is advancing EB-101 our lead product candidate in-- for patients with recessive dystrophic EB.
And we're excited that this is a potential one-time therapy that can offer years of clinical benefit for these patients with large chronic wounds. The pipeline, other pipe portfolio products that we have in the preclinical development, our ophthalmology indication based and these are novel capsids in AAV-based gene therapies that address
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
